Enbrel® is approved across 6 indications, including paediatric indications.¹
RF± polyarthritis and extended oligoarthritis
Safety and efficacy of etanercept in JIA after 13 years of treatment5
Only 6 serious AEs (6.7%) during the 13-year period5
Retrospective data from 90 patients, 38 (42.0%) were male and 52 (58.0%) were female; 15 (16.7%) had systemic onset JIA, 41 (45.6%) had eoJIA, 14 (15.6%) had RF+ pJIA, 18 (20.0%) had RF− pJIA and 2 (2.1%) had ERA. Median age at the start of etanercept treatment was 9 years (range, 3-18 years), median duration of etanercept treatment was 6 years (range, 0.5-13 years).
A very young JIA patient
A JIA patient transitioning from childhood to adolescence
ACR Pedi, American College of Rheumatology Pediatric; AE, adverse event; eoJIA, extended oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-related arthritis; JIA, juvenile idiopathic arthritis; MTX, methotrexate; PsA, psoriatic arthritis; pJIA, polyarticular juvenile idiopathic arthritis; RF+, rheumatoid factor positive; RF−, rheumatoid factor negative; RF±, rheumatoid factors positive or negative.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022